Compare CAR & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAR | SRRK |
|---|---|---|
| Founded | 1946 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.5B |
| IPO Year | 1998 | 2018 |
| Metric | CAR | SRRK |
|---|---|---|
| Price | $176.66 | $45.53 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $136.57 | $56.17 |
| AVG Volume (30 Days) | 686.8K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,652,000,000.00 | N/A |
| Revenue This Year | $2.10 | N/A |
| Revenue Next Year | $1.81 | $534.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $85.96 | $27.07 |
| 52 Week High | $847.70 | $52.19 |
| Indicator | CAR | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 41.60 |
| Support Level | $147.23 | $45.46 |
| Resistance Level | $847.70 | $48.23 |
| Average True Range (ATR) | 10.91 | 2.12 |
| MACD | 5.69 | -0.53 |
| Stochastic Oscillator | 86.41 | 17.45 |
Avis Budget Group Inc is a provider of mobility solutions through its three brands Avis, Budget and Zipcar, as well as several other brands, well recognized in their respective markets. Its brands offer a range of options, from car and truck rental to car sharing. The company operates in two reportable business segments: Americas - (i) vehicle rental operations in North America, South America, Central America and the Caribbean, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly. International - consisting of (i) vehicle rental operations in Europe, the Middle East, Africa, Asia and Australasia, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.